MedTrace Logo

Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis

NCT03824405 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-10-25

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with moderate AD.

Conditions

Interventions

DRUG

BTX 1204

BTX 1204 liquid formulation

DRUG

Vehicle

Vehicle liquid formulation

Sponsors & Collaborators

  • Botanix Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Anthony Robinson, CRNP · Head of Development, Botanix Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-04
Primary Completion
2020-01-27
Completion
2020-03-04
FDA Drug
Yes

Countries

  • United States
  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03824405 on ClinicalTrials.gov